[Analogs of prostaglandin-related substances and inhibitors of their synthesis and metabolism. Clinical application: cardiovascular diseases].
D000787:Angina Pectoris / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use; D003327:Coronary Disease / Q000097:blood; D011464:Epoprostenol / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000097:blood; D008689:Methacrylates / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy*; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D010974:Platelet Aggregation; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D013931:Thromboxanes / Q000097:blood; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage
D008689:Methacrylates; D013931:Thromboxanes; C031517:2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid; D011464:Epoprostenol; D010088:Oxidoreductases; D014568:Urokinase-Type Plasminogen Activator; D013930:Thromboxane-A Synthase; C034364:ozagrel; D001241:Aspirin